APA (7th ed.) Citation

MH, S., P, L., ME, O., FV, F., KN, M., S, B., . . . PJ, W. (2016). Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Investigational new drugs, 34(3), 290. https://doi.org/10.1007/s10637-016-0336-9

Chicago Style (17th ed.) Citation

MH, Shah, Lorigan P, O'Brien ME, Fossella FV, Moore KN, Bhatia S, Kirby M, and Woll PJ. "Phase I Study of IMGN901, a CD56-targeting Antibody-drug Conjugate, in Patients with CD56-positive Solid Tumors." Investigational New Drugs 34, no. 3 (2016): 290. https://doi.org/10.1007/s10637-016-0336-9.

MLA (9th ed.) Citation

MH, Shah, et al. "Phase I Study of IMGN901, a CD56-targeting Antibody-drug Conjugate, in Patients with CD56-positive Solid Tumors." Investigational New Drugs, vol. 34, no. 3, 2016, p. 290, https://doi.org/10.1007/s10637-016-0336-9.